Inhibitory effect of schisandrin B on gastric cancer cells in vitro

Figure 1 Effect of SC-B on gastric cancer SGC-7901 cell proliferation. Gastric cancer SGC-7901 cells were treated with SC-B (final concentration of schisandrin B was 25 mg/L, 50 mg/L and 100 mg/L for the LSC, MSC, and HSC groups, respectively) at the indicated times. A: Optical density values at 490 nm for each group were measured; B: Inhibitory rates (IR) of the 3 dosages are shown at different time points. ^aP < 0.05 vs DMSO group.

Figure 2 Influence of SC-B on the mitosis index of SGC-7901 cells. Gastric cancer SGC-7901 cells were treated with SC-B (final concentration of schisandrin B was 25 mg/L, 50 mg/L, and 100 mg/L for the LSC, MSC, and MSC groups, respectively) at the indicated times; ^aP < 0.05 vs DMSO group.

Figure 3 Effect of SC-B on the cell cycle of gastric cancer SGC-7901 cells. Gastric cancer SGC-7901 cells were treated with SC-B (final concentration of schisandrin B, 50 mg/L) for 48 h. A: Percentage of cell distribution in the G₀/G₁ phase; B: Percentage of cell distribution in the S+G₂M phase; C: Percentage of cell inhibition (PCI). ^aP < 0.05 vs DMSO group.

Figure 4 Flow cytometry results showing the influence of SC-B on the cell cycle of gastric cancer SGC-7901 cells.

Figure 5 Influence of SC-B on cyclinD1 mRNA expression in gastric cancer SGC-7901 cells. Gastric cancer SGC-7901 cells were treated with SC-B (final concentration of schisandrin B, 50 mg/L) for 48 h. A: Electrophoretic bands of cyclinD1 mRNA and GAPDH; B: Half-quantitative results of the expression level of cyclinD1 mRNA, ^aP < 0.05 vs DMSO group.